CN Patent

CN111386128A — 用于免疫调节的联合疗法

Assigned to Aurigene Oncology Ltd · Expires 2020-07-07 · 6y expired

What this patent protects

本公开涉及包括施用抑制VISTA和PD‑1(例如，PD‑1、PD‑L1或PD‑L2)途径的化合物以及抑制TIM‑3和PD‑1(例如，PD‑1、PD‑L1或PD‑L2)途径的化合物的方法。本公开还涉及通过抑制由VISTA、TIM‑3、PD‑1、PD‑L1和/或PD‑L2诱导的免疫抑制性信号来治疗病症。

USPTO Abstract

本公开涉及包括施用抑制VISTA和PD‑1(例如，PD‑1、PD‑L1或PD‑L2)途径的化合物以及抑制TIM‑3和PD‑1(例如，PD‑1、PD‑L1或PD‑L2)途径的化合物的方法。本公开还涉及通过抑制由VISTA、TIM‑3、PD‑1、PD‑L1和/或PD‑L2诱导的免疫抑制性信号来治疗病症。

Drugs covered by this patent

Patent Metadata

Patent number
CN111386128A
Jurisdiction
CN
Classification
—
Expires
2020-07-07
Drug substance claim
No
Drug product claim
No
Assignee
Aurigene Oncology Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.